Krka presented its operating results for the first half of 2014

The Group had sold EUR 599.4 million worth of products and services in the reported period, up 0.4% compared to the same period last year, and had generated EUR 106.6 million of profit (up 6%).

The Krka Company had sold EUR 582.6 million worth of products (down 0.8%) and had generated EUR 98.8 million of profit for the period (up 6%).

Krka Group sales by Region

The leading sales region was Region East Europe, where Krka generated EUR 220.8 million of revenues and which represents 36.8% of overall sales. Compared to the same period last year, sales there increased by EUR 9.6 million, or 5%.

Krka Group sales by product and service group

The Krka Group sold EUR 502.1 million worth of prescription pharmaceuticals in the reported period, just over 1% more than in the same period last year. Prescription pharmaceuticals represent 83.8% of Krka Group sales, their sales having increased in Region South-East Europe (up 13%) and Region East Europe (up 8%).

Non-prescription product sales were down 9% compared to the same period last year, to EUR 58.8 million (9.8% of total Group sales), while animal health product sales were up 3% to EUR 22.7 million, which is 3.8% of overall Group sales. Health resort and tourist services totalled EUR 14.4 million in revenues, up 1% from the same period last year (2.4% of total sales), and other sales revenues amounted to EUR 1.4 million (0.2% of total Group six-month sales).

Research and development

In the first six months of 2014 Krka obtained marketing authorisations for nine new products in 20 dosage forms and strengths, and acquired 219 new marketing authorisations for 83 products in different markets.

Krka was the first generic producer to obtain marketing authorisations for Tenloris (losartan and amlodipine) in the form of film-coated tablets in four strengths, a new medicine used to lower blood pressure, for which approvals were granted under the European Decentralised Procedure (DCP). The complementary effect of the product’s two active substances reduces the likelihood of adverse effects and improves treatment tolerability in patients, by enabling them to take one tablet with a fixed-dose combination of both active substances.

Investments

In the first half of 2014 the Krka Group allocated EUR 88.7 million to investments, of which the controlling company invested EUR 80.3 million and subsidiaries EUR 8.4 million. Investments are primarily increasing and modernising their production capacity, and research and development infrastructure.

Investor and share information

At the end of June 2014 Krka had 62,547 shareholders. The proportion of shareholdings held by international investors increased by 0.5 of a percentage point since the beginning of the year, and currently amounts to 20.8%. On 30 June 2014 Krka’s share traded at EUR 70.00 on the Ljubljana Stock Exchange, up 17% from the year-end of 2013 when it traded at EUR 60.00. Krka’s market capitalisation at the end of June amounted to EUR 2.5 billion.

 

More in press release